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Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer
biopsy and radical prostatectomy specimens
Aims: Intraductal carcinoma (IDC) is an adverse
histopathological parameter for prostate cancer out-
come, but is not incorporated in current tumour grad-
ing. To account for its dismal prognosis and to omit
basal cell immunohistochemistry, it has been proposed
to grade IDC on the basis of its underlying architectural
pattern. The aim of this study was to determine the
impact of IDC grade assignment on prostate cancer
biopsy and radical prostatectomy tumour grading.
Methods and results: A cohort of 1031 prostate can-
cer biopsies and 835 radical prostatectomies were
assigned a Grade Group according to the 2014 Inter-
national Society of Urological Pathology guidelines,
without incorporation of IDC in grading. Tumour
grading was compared with a Grade Group in which
IDC was graded on the basis of its underlying archi-
tecture. Of 1031 biopsies, 139 (13.5%) showed IDC.
Grade assignment of IDC led to a Grade Group
change in 17 (1.6%) cases: four of 486 (0.8%) Grade
Group 1 cases were reclassified as Grade Group 2,
nine of 375 (2.4%) Grade Group 2 cases were reclas-
sified as Grade Group 3, and four of 58 (6.9%) Grade
Group 4 cases were reclassified as Grade Group 5.
IDC was observed in 213 of 835 (25.5%) radical
prostatectomies, and its grading led to a change in
tumour grade in five of 835 (0.6%) patients, with
upgrading in two of 207 (1.0%) patients with Grade
Group 1 cancer, in two of 420 (0.5%) patients with
Grade Group 2 cancer, and in one of 50 (2%)
patients with Grade Group 4 cancer.
Conclusion: IDC grade assignment led to a Grade
Group change in 1.6% of prostate biopsy specimens
and in 0.6% of radical prostatectomy specimens.
Although the inclusion of IDC in or the exclusion of
IDC from the Grade Group might affect decision-mak-
ing in individual patients, it has a minimal impact on
overall prostate cancer management.
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Introduction
The Gleason score/Grade Group system is one of the
main parameters used to predict clinical outcome and
to guide treatment in prostate cancer patients. For
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instance, patients with Gleason score 6 (Grade Group
1) prostate cancer are often eligible for active surveil-
lance, whereas those with Gleason score ≥7 (Grade
Group ≥2) are usually offered active treatment. Apart
from Gleason grading, additional pathological param-
eters have been identified with independent predictive
value for disease behaviour, and these are increas-
ingly being used for therapeutic decision-making.1
Intraductal carcinoma (IDC) of the prostate is
defined as a proliferation of malignant epithelial cells
confined to acini and dilated pre-existing glands. In
the vast majority of cases, IDC is accompanied by
invasive prostate carcinoma, although rare cases of
pure IDC have been reported.2 IDC accompanied by
invasive carcinoma in prostate biopsy and radical
prostatectomy specimens has been associated with
increased biochemical recurrence, metastasis, and dis-
ease-specific death.2–7 The 2014 International Society
of Urological Pathologists (ISUP) consensus confer-
ence recommended that IDC without concomitant
invasive carcinoma should be reported, with a com-
ment stating that it was usually associated with
aggressive disease, which was endorsed by the 2016
World Health Organization (WHO) classification of
prostate carcinoma.1,8 Reporting of IDC admixed with
invasive carcinoma, however, has been a matter of
debate.
To better convey the aggressive nature of IDC and
to omit basal cell immunohistochemistry for its dis-
tinction from invasive cribriform and solid fields, it
has been proposed to include IDC associated with
invasive carcinoma in prostate cancer grading.9 Fur-
thermore, a recent publication highlighted problems
and controversies regarding the systematic reporting
of IDC, in part because of the current lack of guideli-
nes, which might be overcome by including IDC in
grading schemes.26
Little is known about what impact grading of IDC
associated with invasive carcinoma has on Grade
Group assignment in prostate cancer patients. The
objective of this study was to determine the effect on
Grade Group assignment of IDC being graded on the
basis of its underlying architectural pattern in a large
prostate cancer biopsy and radical prostatectomy
cohort.
Materials and methods
P A T I E N T S E L E C T I O N
This study included separate prostate cancer biopsy
and radical prostatectomy cohorts, which have been
reported on by our group previously.11,12 The biopsy
cohort consisted of 1031 patients from the Dutch
part of the European Randomized Study of Screening
for Prostate Cancer who had been diagnosed with
prostate cancer between November 1993 and March
2000 in Erasmus MC, University Medical Centre, Rot-
terdam, The Netherlands. All patients underwent sex-
tant biopsies, and one or two additional biopsies were
also performed if a suspicious lesion was detected
with transrectal ultrasound.13,14 The radical prostate-
ctomy cohort consisted of 835 patients who had
undergone surgery for prostate cancer without prior
radiation or hormonal therapy at the same institute
between 2000 and 2017. After fixation, the radical
prostatectomy specimens were sectioned transversely
and entirely embedded for diagnostic purposes. All
slides were available for pathology review. Except for
two cases, there was no overlap between the biopsy
cohort and the prostatectomy cohort. The use of tis-
sue samples for scientific purposes was approved by
the institutional Medical Research Ethics Committee
(MEC-2018-1614).
P A T H O L O G I C A L E V A L U A T I O N
The biopsies were reviewed in common sessions by
three investigators (C.K., I.K., and G.v.L.), and the
radical prostatectomy specimens were reviewed in
common sessions by two investigators (E.H. and
G.v.L.), who were all blinded to patient information
and outcome. For each biopsy core, the following
were recorded: Gleason score, cancer length in mil-
limetres, percentages of Gleason patterns 3, 4 and 5,
and the presence and percentage of IDC. Biopsy
tumour length included both invasive carcinoma and
IDC. For each patient, a global Gleason score was
determined as follows. For each biopsy, the lengths
(mm) of individual Gleason patterns 3, 4 and 5 and
IDC were calculated by multiplying the percentage of
each component by tumour length. The lengths of
the individual components in different biopsies were
added, and divided by the total tumour length from
all positive biopsies, resulting in percentages of Glea-
son pattern 3, 4 and 5 and IDC for the entire case.
These parameters were used to calculate the Grade
Group according to the 2014 ISUP/2016 WHO rec-
ommendations.1 IDC was incorporated in the Grade
Group by adding its percentage to Gleason pattern 4
in cases of cribriform architecture and to pattern
Gleason 5 in cases of solid architecture or comedo
necrosis, before application of the same grading rules.
This study included only IDC cases associated with
invasive carcinoma, and not isolated IDC cases with-
out invasive disease, which should not be graded.
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The following features were recorded at review of
radical prostatectomy specimens: Gleason score/Grade
Group according to the 2014 ISUP/2016 WHO
guidelines, pT stage according to the American Joint
Committee on Cancer TNM 8th edition, surgical mar-
gin status, percentages of Gleason pattern 3, 4, and
5, and the presence and percentage of IDC. For incor-
poration of IDC in Grade Group assignment, its per-
centage was added to Gleason pattern 4 or 5, and the
Grade Group was then determined. In radical prosta-
tectomies, Gleason patterns 4 and 5 were considered
to be a tertiary pattern if they occupied <5% of the
tumour area.
Both the biopsy cohort and the radical prostatec-
tomy cohort have been used for investigation of the
added clinical value of invasive cribriform carcinoma
and IDC.11,15–17 Particular effort was made to distin-
guish these entities. Invasive cribriform Gleason pat-
tern 4 was morphologically distinguished from IDC
on the basis of the following features. Invasive cribri-
form prostate cancer had an irregular outline, and
showed anastomosing fields beyond pre-existing gland
architecture or extension into periprostatic adipose
tissue, ejaculatory ducts, or seminal vesicles. IDC was
morphologically identified if cribriform structures
were clearly continuous with pre-existing glands lined
by basal epithelium or contained corpora amylacea. If
invasive cribriform carcinoma and IDC could not be
differentiated by the use of morphological criteria
alone, additional immunohistochemical 34BE12
staining for the presence of basal cells was performed:
this applied to 104 of 197 (52.8%) prostate cancer
biopsies with cribriform or solid architecture, and to
189 of 417 (45.3%) radical prostatectomy specimens
with these features.
S T A T I S T I C A L A N A L Y S I S
Differences between percentages of Gleason pattern 4
with exclusion and inclusion of IDC were analysed in
Grade Group 2 and 3 patients by the use of Student’s
t-test. Statistical analyses were performed with SPSS
version 24 (IBM, Chicago, IL, USA). Results were
considered to be significant when the two-sided P-
value was <0.05.
Results
P A T I E N T C H A R A C T E R I S T I C S O F T H E B I O P S Y
C O H O R T
The prostate biopsy cohort included 1031 patients
with a median age of 66 years [interquartile range
(IQR) 62–71 years] and a prostate-specific antigen
(PSA) level of 5.6 ng/ml (IQR 3.9–8.8 ng/ml). Sex-
tant biopsies were performed in 649 (53.3%) patients,
and one or two additional biopsies were performed in
460 (44.6%) and 22 (2.1%) patients, respectively.
Four hundred and eighty-six (47.1%) patients had
global Grade Group 1 cancer, 375 (36.4%) had Grade
Group 2 cancer, 63 (6.1%) had Grade Group 3 can-
cer, 58 (5.6%) had Grade Group 4 cancer, and 49
(4.8%) had Grade Group 5 cancer.
I M P A C T O F I D C I N C O R P O R A T I O N O N T H E
G R A D I N G O F P R O S T A T E C A N C E R B I O P S I E S
In total, 139 (13.5%) patients had IDC in one or
more biopsies associated with invasive adenocarci-
noma, of whom four (0.8%) had Grade Group 1 can-
cer, 70 (18.7%) had Grade Group 2 cancer, 22
(34.9%) had Grade Group 3 cancer, 19 (32.8%) had
Grade Group 4 cancer, and 24 (9.0%) had Grade
Group 5 cancer. Incorporation of IDC in the Grade
Group by considering it as Gleason pattern 4 led to a
change in the Grade Group in 17 cases (1.6%). None
of the patients was reclassified by assignment of Glea-
son pattern 5 to IDC with solid growth or come-
donecrosis. Four (0.8%) of 486 Grade Group 1
patients had IDC, and these were reclassified as Grade
Group 2; nine of 375 (2.4%) patients with Grade
Group 2 cancer were upgraded to Grade Group 3;
and four of 58 (6.9%) patients with Grade Group 4
cancer were upgraded to Grade Group 5 (Table 1).
The last four cases were all reclassified from Gleason
score 3 + 5 = 8 with tertiary Gleason pattern 4 to
Gleason score 4 + 5 = 9.
As the percentage of Gleason pattern 4 is an inde-
pendent pathological parameter for prostate cancer
outcome, we also assessed the influence of grade
assignment of IDC on Gleason pattern quantity.18–20
When IDC was not assigned a grade and was quanti-
fied as a separate entity, the mean percentage of
invasive Gleason pattern 4 in the 375 global Grade
Group 2 patients was 17.8% [standard deviation (SD)
12.2%]. When IDC was incorporated in the grading
system and quantified as Gleason pattern 4 in the
reassigned 370 Grade Group 2 patients, the Gleason
pattern 4 percentage was 18.5% (SD 12.8%;
P = 0.44). The percentages of Gleason pattern 4 in
Grade Group 3 patients without and with incorpora-
tion of IDC were 65.9% (SD 13.4%) in 63 patients
and 67.6% (SD 11.8%) in 72 patients, respectively
(P = 0.42). When only biopsies containing IDC were
analysed, the percentage of Gleason pattern 4
increased from 21.9% (SD 10.8%) in 70 Grade Group
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2 patients without IDC grade assignment to 26.2%
(SD 12.4%) in 65 Grade Group 2 patients with IDC
grade assignment (P = 0.03). Although the percent-
age of Gleason pattern 4 increased from 58.5% (SD
13.4%) in 22 Grade Group 3 patients to 64.7% (SD
11.3%) in 31 Grade Group 3 patients, this did not
meet conventional measures of significance
(P = 0.08) in this relatively small subset.
P A T I E N T C H A R A C T E R I S T I C S O F T H E R A D I C A L
P R O S T A T E C T O M Y C O H O R T
The radical prostatectomy cohort consisted of 835
patients with a median age of 65 years (IQR 60–
68 years) and a median PSA level of 8.2 ng/ml (IQR
5.7–13.0 ng/ml). Two hundred and seven (24.8%)
patients had Grade Group 1 cancer, 420 (50.3%) had
Grade Group 2 cancer, 101 (12.1%) had Grade
Group 3 cancer, 50 (6.0%) had Grade Group 4 can-
cer, and 57 (6.8%) had Grade Group 5 cancer.
Pathological stage was distributed as follows: 476
(57.0%) pT2, 263 (31.5%) pT3a, 93 (11.1%) pT3b,
and three (0.4%) pT4. In total, 284 (34.0%) patients
had a positive surgical margin.
I M P A C T O F I D C I N C O R P O R A T I O N O N T H E
G R A D I N G O F R A D I C A L P R O S T A T E C T O M I E S
IDC was observed in 213 of 835 (25.5%) patients,
and was present in four of 207 (1.9%) with Grade
Group 1 cancer, 103 of 420 (14.5%) with Grade
Group 2 cancer, 51 of 101 (50.5%) with Grade
Group 3 cancer, 20 of 50 (40.0%) with Grade Group
4 cancer, and 35 of 57 (61.4%) with Grade Group 5
cancer. Incorporation of IDC in Grade Group assign-
ment led to a change in tumour grade in five of 835
(0.6%) patients: upgrading of two of 207 (1.0%) with
Grade Group 1 cancer, two of 420 (0.5%) with
Grade Group 2 cancer, and one of 50 (2.0%) with
Grade Group 4 cancer (Table 2). In these cases,
upgrading resulted from the assignment of Gleason
pattern 4 to cribriform IDC. No cases were upgraded
as a result of grade assignment to IDC with a solid
growth pattern or comedonecrosis.
When IDC was not assigned a grade and was
quantified as a separate entity, the percentage of
invasive Gleason pattern 4 was 20.7% (SD 11.4%)
among 420 Grade Group 2 patients. The percentage
of Gleason pattern 4 was 21.9% (SD 12.2%) among
419 Grade Group 2 patients in whom IDC was
assigned a grade and quantified as Gleason pattern 4
(P = 0.14). When IDC was excluded from grade
assignment and Gleason pattern 4 quantity among
101 Grade Group 4 patients, the percentage of Glea-
son pattern 4 was 68.5% (SD 11.2%), as compared
with 71.4% (SD 11.7%; P = 0.07) among 104
patients with inclusion of IDC in grade and Gleason
pattern 4 quantity. When only Grade Group 2 radical
prostatectomies were included with IDC, the percent-
age of Gleason pattern 4 increased from 25.3% (SD
10.3%) in 103 patients without IDC grade assign-
ment to 30.3% (SD 11.3%) in 103 patients with IDC
grade assignment (P = 0.001). For Grade Group 3
patients with IDC, the percentage of Gleason pattern
4 increased from 66.9% (10.5%) in 51 patients to
72.6% (SD 11.6%) in 54 patients (P = 0.01).
Discussion
The independent adverse prognostic value of IDC has
been well acknowledged. Because IDC is a lesion
within pre-existing prostate glandular structures, it
was not taken into account in prostate cancer
Table 1. Impact of Grade Group in prostate cancer biopsies (n = 1031) if intraductal carcinoma (IDC) is assigned a tumour
grade as if it were invasive disease
Prostate biopsy
Grade Group with IDC grade assignment
1 2 3 4 5 Total
Grade Group without IDC grade assignment 1 482 4 – – – 486
2 – 366 9 – – 375
3 – – 63 – – 63
4 – – – 54 4 58
5 – – – – 49 49
Total 482 370 72 54 53 1031
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grading according to the 2014 ISUP and 2016 WHO
guidelines. In recent years, several arguments have
been raised in favour of incorporation of IDC in pros-
tate cancer grading. In the current study, we investi-
gated its impact on Grade Group assignment in a
biopsy cohort and a radical prostatectomy cohort. We
found that incorporation IDC in tumour grading as if
were an invasive structure led to minor changes in
Grade Groups, ranging from 1.6% in biopsy speci-
mens to 0.6% in radical prostatectomy specimens.
Although incorporation of IDC might affect decision-
making in individual patients, it has, overall, a mini-
mal impact on grading in prostate cancer popula-
tions.
Many groups have shown the independent predic-
tive value of IDC in prostate cancer biopsy and radi-
cal prostatectomy cohorts.2–7 The 2014 ISUP
consensus conference and WHO 2016 both recom-
mended reporting of IDC without invasive disease,
but the evaluation and reporting practices for IDC
admixed with carcinoma are less clear.1,8 Recently, it
has been debated whether IDC should be integrated
in prostate cancer grading.9 The most important
argument for not grading IDC associated with inva-
sive carcinoma is that it is not an invasive lesion in
itself. On the other hand, assigning a grade to IDC is
easier in daily clinical practice. Morphologically, IDC
can closely resemble invasive cribriform Gleason pat-
tern 4, or solid and comedonecrosis pattern 5. In fact,
two studies have shown that comedonecrosis is more
frequent in IDC than in invasive Gleason pattern
5.21,22 Their distinction often requires basal cell
immunohistochemistry, in which a complete lack of
basal cells would favour invasive disease, whereas the
presence of a local, scattered or continuous basal cell
layer is more compatible with IDC. Although
immunohistochemistry is helpful in many cases, it is
not conclusive in every case. For instance, it is well
established that basal cells may be absent in some
high-grade prostatic intraepithelial neoplasia glands,
owing to sampling artefacts. As glands with IDC are,
by definition, distended, the chance of there being
basal cell sampling artefacts would be even larger in
IDC, leading to a false diagnosis of invasive carci-
noma. On the other hand, irregular cribriform fields
substantially exceeding the pre-existing gland archi-
tecture but with sporadic basal cells should be consid-
ered to represent invasive carcinoma, as has also
been observed for rare Grade Group 1 tumours.23
In the current study, we found that inclusion of
IDC associated with invasive carcinoma in tumour
grading led to a change in Grade Group assignment
in only 1.6% of all prostate cancer biopsy specimens
and in only 0.6% of radical prostatectomy specimens.
For distinction of IDC from invasive cribriform or solid
carcinoma, we performed basal cell immunohisto-
chemistry on one or more slides of 52.8% of prostate
cancer biopsies and 45.3% of radical prostatectomies
with these morphological features. In a recent pros-
tate biopsy study, Chen-Maxwell et al. identified 123
cases of IDC admixed with invasive carcinoma in
4630 patients, of whom 2726 had a positive biopsy
(personal communication).24 After application of
basal cell immunohistochemistry in 83% of these,
they found a change in global Grade Group in 28
(23%) patients, representing 1.0% of their prostate
cancer population, which is comparable to our 1.6%
biopsy Grade Group change. In both studies, a signifi-
cant number of immunohistochemical stains were
used on samples with cribriform or solid architecture,
ranging from 45% to 83%, to differentiate IDC from
invasive disease, with a Grade Group change in a
minority of cases. In the latest 2019 ISUP consensus
meeting on prostate cancer grading in Nice, France,
Table 2. Impact of Grade Group in radical prostatectomy specimens (n = 835) if intraductal carcinoma (IDC) is assigned a
tumour grade as if it were invasive disease
Radical prostatectomy
Grade Group with IDC grade assignment
1 2 3 4 5 Total
Grade Group without IDC grade assignment 1 205 1 1 – – 207
2 – 418 2 – – 420
3 – – 101 – – 101
4 – – – 49 1 50
5 – – – – 57 57
Total 205 419 104 49 58 835
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it was agreed that IDC associated with invasive carci-
noma should be graded on the basis of its underlying
architectural pattern as if it were invasive disease.25
The most important reasons for this recommendation
were: (i) that it accounts for the adverse clinicopatho-
logical features associated with IDC, which is particu-
larly important for men with Grade Group 1 cancers
with IDC, who are at risk for undertreatment of their
disease; and (ii) the omission of significant numbers
of immunohistochemical stains, including those for
which interpretation is arbitrary.26 Our finding that
exclusion of IDC from prostate cancer grading is asso-
ciated with a Grade Group change in <2% of cases is
supportive of this practical 2019 ISUP recommenda-
tion.
A recent interobserver study among 42 genitouri-
nary pathologists highlights current practice on the
utilisation of immunohistochemistry and reporting of
IDC.10 This study reflects the 2016 WHO practices,
with the majority of participants not incorporating
IDC in Grade Group assignment in biopsy and radical
prostatectomy specimens. Some of the current contro-
versies also become clear in this study, as the major-
ity included IDC in tumour volume assessment, and
88% rarely, if ever, employed immunohistochemistry
in assigning Grade Group and/or Gleason pattern 4
or 5 quantification. Although Gleason pattern 4
quantification is recommended for all Gleason score 7
(Grade Groups 2 and 3) prostate cancers, it is not
clear to what extent this estimate includes IDC.8,25
Grading practices of including IDC in tumour volume
assessment and possibly Gleason pattern 4 quantifica-
tion, but not in tumour grading, seem contradictory.
The 2019 ISUP recommendation on grading of IDC
associated with invasive adenocarcinoma is helping
to overcome these inconsistencies.
The strength of this study is the use of large, well-
characterised biopsy and radical prostatectomy
cohorts, in which extensive immunohistochemistry
had been used for distinction of IDC and invasive car-
cinoma. A disadvantage is that this study included
sextant biopsies from the 1990s, whereas standard
current practice is to obtain more biopsies with addi-
tional magnetic resonance imaging-targeted sam-
pling. Furthermore, despite the use of extensive
immunohistochemistry, it was not performed on each
case for practical reasons. Although we interpreted
cribriform lesions with basal cells as IDC, and those
without as invasive carcinoma, definitive classifica-
tion might be arbitrary in some cases.23,27 Finally,
we compared global biopsy Grade Groups and did not
study the effects of IDC grade incorporation in single
biopsies with the worst Grade Group, which might
result in more pronounced changes in grading. Apart
from investigating the effects of IDC grading on Grade
Group assignment, we also wanted to obtain insights
into the alteration in the Gleason pattern 4 percent-
age, which is more comprehensive for the entire case
than for individual biopsy cores.
In conclusion, we have demonstrated that the
incorporation of IDC in prostate cancer Grade Groups
on the basis of its underlying architecture led to a
change in Grade Group assignment in <2% of pros-
tate cancer biopsies and radical prostatectomies.
Given the minimal impact of excluding IDC from
prostate cancer grading, this study supports the prac-
tical 2019 ISUP recommendations on grading of IDC
associated with invasive carcinoma.
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